e-learning
resources
Berlin 2001
Monday 24.09.2001
Rare and unusual diseases or problems
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up
I. S. A. Cerveri, G. Rodi, M. C. Zoia, P. Pochetti, D. Fiorenza, S. Colato, A. Corsico, M. Luisetti (Pavia, Italy)
Source:
Annual Congress 2001 - Rare and unusual diseases or problems
Session:
Rare and unusual diseases or problems
Session type:
Thematic Poster Session
Number:
1532
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. S. A. Cerveri, G. Rodi, M. C. Zoia, P. Pochetti, D. Fiorenza, S. Colato, A. Corsico, M. Luisetti (Pavia, Italy). Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up. Eur Respir J 2001; 16: Suppl. 31, 1532
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004
Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 23: 526-531
Year: 2004
A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP).
Source: International Congress 2017 – Novel and old entities
Year: 2017
The benefits of whole lung lavage in pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 23: 503-505
Year: 2004
Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 83s
Year: 2005
Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?
Source: International Congress 2015 – IIPs: orphan
Year: 2015
KL-6 in whole lung lavage fluid of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease
Year: 2009
Pulmonary alveolar proteinosis
Source: Respipedia Article
Year: 2017
Characterization of the gene network driving the whole lung lavage (WLL) outcome in Pulmonary Alveolar Proteinosis (PAP).
Source: International Congress 2018 – Progress in rare interstitial lung diseases
Year: 2018
Whole lung lavage with intermittent double lung ventilation: a new technique for managing pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 91s
Year: 2004
Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005
Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Long term follow up of the whole lung lavage programme in patients with pulmonary alveolar proteinosis: an update
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume?
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child
Source: Eur Respir J 2003; 22: Suppl. 45, 309s
Year: 2003
The value of the whole lung lavage for patients with pulmonaryalveolar proteinosis
Source: Annual Congress 2009 - Trends in bronchoscopy
Year: 2009
Pulmonary alveolar proteinosis and long-term outcome after bronchopulmonary lavage
Source: International Congress 2017 – Paediatric bronchology
Year: 2017
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept